Weekly Digest - October 2024
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - October 2024
14 Oct 2024: SystImmune, Inc. announces FDA clearance of IND application for BL-M11D1 in relapsed/refractory Acute Myeloid Leukemia
- SystImmune, Inc. announced that the FDA has cleared its IND application for BL-M11D1, ADC targeting CD33, supporting the start of a Phase 1 trial for relapsed/refractory Acute Myeloid Leukemia (AML) patients
- This milestone underscores SystImmune’s commitment to advancing its pipeline of novel therapeutic candidates
- BL-M11D1 is designed to trigger antibody-dependent cellular cytotoxicity (ADCC) and delivers a topoisomerase I inhibitor payload to kill cancer cells by binding to CD33
- SystImmune, based in Redmond, WA, focuses on developing innovative cancer treatments, with a pipeline that includes several clinical-stage assets for both solid tumors and hematologic indications
